Eloxx Pharmaceuticals, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Filed November 13, 2023. Eloxx is a clinical-stage biopharmaceutical company developing ribosome-modulating drug candidates for rare diseases; it reported no product or service revenue.
Financial performance and position
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $1.25m | $4.88m | $7.08m | $20.43m |
| General and administrative expense | $2.39m | $2.26m | $6.18m | $7.96m |
| Total operating expenses | $3.64m | $7.14m | $13.26m | $28.39m |
| Net loss | $3.59m | $7.51m | $14.16m | $29.75m |
| Basic and diluted loss per share | $1.31 | $3.47 | $5.96 | $13.73 |
| Cash used in operating activities | Not separately stated for the quarter | $12.33m | $26.18m |
Operating margins are not meaningful because the company has no revenue. Lower R&D spending was primarily associated with reduced cystic-fibrosis development and Cystic Fibrosis Foundation-funded activity. Q3 other income included a $0.27m gain from the change in fair value of warrant liabilities and a $0.26m gain on sale of fixed assets, partly offset by interest expense and other items.
At September 30, cash and cash equivalents were $4.78m, restricted cash $0.22m, total current assets $5.63m, and total current liabilities $23.47m—approximately $17.84m of negative working capital. Total assets were $6.04m, total liabilities $26.09m, and stockholders’ deficit $20.05m. The company reported $4.8m of Hercules loan principal outstanding; scheduled principal payments were underway, with maturity on April 1, 2025. The loan bears a floating rate (14.75% at September 30; effective rate 19.4%).
Material changes and financing
- Nine-month net loss narrowed 52% year over year, reflecting a 65% reduction in R&D expense and a 22% reduction in G&A. Operating cash use also declined substantially versus 2022.
- Financing cash flow included $7.72m of term-loan principal repayments, offset by $3.15m net ATM proceeds and $1.74m net proceeds from a September registered direct offering. The offering generated $2.0m gross and included common shares, pre-funded warrants, and warrants.
- The company had sold approximately $3.5m gross under its ATM program by the filing date, subject to Form S-3 offering limits. Following the Nasdaq trading suspension, ATM sales were unavailable under the agreement unless the sales agent agreed otherwise.
- Common shares outstanding were 3,068,390 at September 30 and 3,143,390 as of November 9. The September offering and ATM sales diluted existing holders; additional warrants may create further dilution. The September common and placement-agent warrants are recorded as liabilities and remeasured at fair value.
- The Cystic Fibrosis Foundation provided a final $0.2m closeout milestone payment in July; the remaining $7.4m under its 2022 award was no longer available for the current program. Up to $1.8m remained potentially available under a separate 2021 award.
Outlook, developments and key risks
- Going concern and liquidity: Management stated September 30 cash would not fund current and planned operations for the next 12 months and concluded substantial doubt existed about the company’s ability to continue as a going concern. The risk summary says substantial additional funding would be needed by January 2024. Financing plans—equity or debt offerings, collaborations, or other sources—were not assured. Failure to raise capital could force spending cuts, workforce reductions, or delay, curtailment, or termination of development programs.
- Debt covenant: The company was in compliance at September 30 with the Hercules minimum qualified cash covenant. A November 10 amendment temporarily set the minimum at $2.25m from November 15 through December 15, 2023, unless extended; afterward it reverts to $2.25m plus qualifying overdue payables. A breach without waiver could accelerate repayment.
- Nasdaq: Trading was suspended October 16, 2023 for failure to meet the $35m market-value-of-listed-securities requirement; shares moved to OTC Pink under ELOX. An appeal was pending at filing, and Nasdaq stated it would not delist the securities before a final written decision. OTC trading may reduce liquidity and impair fundraising.
- ELX-02 in Alport syndrome: The Phase 2 monotherapy study treated three patients for two months. The company reported increased collagen IV alpha 5 staining, qualitative biopsy improvements in podocyte morphology, and an average 60% increase in filtration slit density. Proteinuria results were mixed. These small, preliminary observations are not proof of efficacy. After the period, management said it intended, subject to funding, to seek FDA alignment on a pivotal-trial design and possibly pursue Breakthrough Therapy Designation.
- Other programs: ELX-02 development in cystic fibrosis was paused after a Phase 2 combination study failed to achieve statistical significance on efficacy endpoints. The FDA cleared ZKN-013 for a single-ascending-dose healthy-volunteer trial for RDEB; further development was funding-dependent, and the company was seeking a strategic partner. The filing also describes an FDA partial clinical hold requiring additional pharmacokinetic information before further multiple-dose testing in a referenced program.
- Other risks: No approved products, continuing losses, uncertain clinical and regulatory outcomes, rare-disease recruitment challenges, potential adverse events (including renal toxicity observed in preclinical ELX-02 testing at higher doses), dependence on third-party manufacturers and research partners, potential dilution, and exposure to debt covenant and collaboration repayment or royalty provisions.
Most important facts for investors to verify
- Available cash, actual operating runway, and whether financing or a strategic partnership was secured after the filing.
- Nasdaq Listing Council appeal outcome, current trading venue, and the practical availability of ATM financing.
- Hercules covenant compliance after the temporary amendment expired or was extended, and scheduled debt payments.
- Full and follow-up Alport trial data, including proteinuria, safety, durability, and the FDA’s view of a pivotal study.
- ZKN-013 trial progress and funding; status of paused cystic-fibrosis development and remaining CFF award availability.
- Share-count changes, warrant terms and valuation, and potential dilution from future capital raises.